Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 3, 2013, Pages 414-423

  Calzetta, Luigino ^a   Page, Clive P ^b   Spina, Domenico ^b   Cazzola, Mario ^c   Rogliani, Paola ^c   Facciolo, Francesco ^d   Matera, Maria Gabriella ^e  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

[9,10 DIMETHOXY 2 (2,4,6 TRIMETHYLPHENYLIMINO) 3 (N CARBAMOYL 2 AMINOETHYL) 3,4,6,7 TETRAHYDRO 2H PYRIMIDO[6,1 A]ISOQUINOLIN 4 ONE]; ATROPINE; GLYCOPYRRONIUM BROMIDE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; RPL 554; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRONCHUS MUSCLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ELECTRIC FIELD; ELECTROSTIMULATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MUSCLE CONTRACTILITY; PRIORITY JOURNAL; SMOOTH MUSCLE RELAXATION; SMOOTH MUSCLE TONE;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ATROPINE; BRONCHI; DRUG SYNERGISM; ELECTRIC STIMULATION; FEMALE; GLYCOPYRROLATE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; MUSCLE TONUS; MUSCLE, SMOOTH; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 4 INHIBITORS; PYRIMIDINONES;

EID: 84882399041     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.204644     Document Type: Article

References (71)

1. Banner KH, Moriggi E, Da Ros B, Schioppacassi G, Semeraro C, and Page CP (1996) The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Br J Pharmacol 119: 1255-1261.
2. Banner KH and Press NJ (2009) Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol 157:892-906.
3. Beavo JA and Brunton LL (2002) Cyclic nucleotide research-still expanding after half a century. Nat Rev Mol Cell Biol 3:710-718.
4. Berenbaum MC (1977) Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol 28:1-18.
5. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93-141.
6. Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, Andreoni S, and Neder JA (2010) Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med 104:1288-1296.
7. Bingham J, Sudarsanam S, and Srinivasan S (2006) Profiling human phosphodiesterase genes and splice isoforms. Biochem Biophys Res Commun 350:25-32.
8. Binks AP, Paydarfar D, Schachter SC, Guz A, and Banzett RB (2001) High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects. Respir Physiol 127:125-133.
9. Black JW, Jenkinson DH, and Kenakin TP (1980) Antagonism of an indirectly acting agonist: block by propranolol and sotalol of the action of tyramine on rat heart. Eur J Pharmacol 65:1-10.
10. Blease K, Burke-Gaffney A, and Hellewell PG (1998) Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 124:229-237.
11. Boik JC, Newman RA, and Boik RJ (2008) Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study. Stat Med 27:1040-1061.
12. Boswell-Smith V, Cazzola M, and Page CP (2006a) Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 117:1237-1243.
13. Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, and Page CP (2006b) The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl- 2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a] isoquinolin-4-one]. J Pharmacol Exp Ther 318:840-848.
14. Boucher AN and Tam VH (2006) Mathematical formulation of additivity for antimicrobial agents. Diagn Microbiol Infect Dis 55:319-325.
15. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, and Martinez FJ; M2-124 and M2-125 study groups (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685-694.
16. Calzetta L, Spina D, Cazzola M, Page CP, Facciolo F, Rendina EA, and Matera MG (2011) Pharmacological characterization of adenosine receptors on isolated human bronchi. Am J Respir Cell Mol Biol 45:1222-1231.
17. Cazzola M, Calzetta L, Page CP, Rinaldi B, Capuano A, and Matera MG (2011) Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. Am J Respir Cell Mol Biol 45:704-710.
18. Cazzola M, Calzetta L, Segreti A, Rogliani P, and Page C (2013) Safety and bronchodilator effects of nebulised RPL 554, a novel dual PDE3/4 inhibitor in COPD (Abstract). Am J Respir Crit Care Med 187:A1497.
19. Cazzola M, Noschese P, Salzillo A, De Giglio C, D?Amato G, and Matera MG (2005) Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 99:524-528.
20. Cazzola M, Page CP, Calzetta L, and Matera MG (2012a) Emerging antiinflammatory strategies for COPD. Eur Respir J 40:724-741.
21. Cazzola M, Page CP, Calzetta L, and Matera MG (2012b) Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 64:450-504.
22. Coleman RA, Nials AT, Rabe KF, Vardey CJ, and Watson N (1996) Isolated, electrically-stimulated airway preparations-their use in determining betaadrenoceptor agonist activity. Pulm Pharmacol 9:107-117.
23. Conti M, Richter W, Mehats C, Livera G, Park JY, and Jin C (2003) Cyclic AMPspecific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496.
24. de Boer J, Philpott AJ, van Amsterdam RG, Shahid M, Zaagsma J, and Nicholson CD (1992) Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol 106:1028-1034.
25. Franciosi L, Zuiker R, Kammerling IM, Burgraaf J, Cohen A, Walker M, and Page C (2013) RPL554, a dual PDE3/4 inhibitor, is well tolerated and maintains bronchodilator activity when administered by inhalation to mild-to-moderate allergic asthmatics on 6 consecutive days (Abstract). Am J Respir Crit Care Med 187:A3875.
26. Freas W, Hart JL, Golightly D, McClure H, and Muldoon SM (1989) Contractile properties of isolated vascular smooth muscle after photoradiation. Am J Physiol 256:H655-H664.
27. Gantner F, Götz C, Gekeler V, Schudt C, Wendel A, and Hatzelmann A (1998) Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 123: 1031-1038.
28. Gantner F, Schudt C, Wendel A, and Hatzelmann A (1999) Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function. Pulm Pharmacol Ther 12:377-386.
29. Giembycz MA, Corrigan CJ, Seybold J, Newton R, and Barnes PJ (1996) Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD41 and CD81 Tlymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118:1945-1958.
30. Goldoni M and Johansson C (2007) A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol In Vitro 21:759-769.
31. Goodman LS, Gilman A, and Brunton LL (2008) Goodman & Gilman?s Manual of Pharmacology and Therapeutics, McGraw-Hill Medical, New York.
32. Grabovsky Y and Tallarida RJ (2004) Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther 310:981-986.
33. Greco WR, Bravo G, and Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331-385.
34. Grootendorst DC, Gauw SA, Benschop N, Sterk PJ, Hiemstra PS, and Rabe KF (2003) Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm Pharmacol Ther 16:341-347.
35. Hatake K and Wakabayashi I (2000) Ethanol suppresses L-arginine-induced relaxation response of rat aorta stimulated with bacterial lipopolysaccharide. Nihon Arukoru Yakubutsu Igakkai Zasshi 35:61-68.
36. Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297: 267-279.
37. Hewson CA, Patel S, Calzetta L, Campwala H, Havard S, Luscombe E, Clarke PA, Peachell PT, Matera MG, and Cazzola M,, et al. (2012) Preclinical evaluation of an inhibitor of cytosolic phospholipase A2a for the treatment of asthma. J Pharmacol Exp Ther 340:656-665.
38. Kenakin T, Jenkinson S, and Watson C (2006) Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319:710-723.
39. Lee SI (2010) Drug interaction: focusing on response surface models. Korean J Anesthesiol 58:421-434.
40. Le Jeune IR, Shepherd M, Van Heeke G, Houslay MD, and Hall IP (2002) Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J Biol Chem 277:35980-35989.
41. Matera MG, Calzetta L, Parascandolo V, Curradi G, Rogliani P, and Cazzola M (2009) Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. Pulm Pharmacol Ther 22:478-482.
42. Matera MG, Calzetta L, Passeri D, Facciolo F, Rendina EA, Page C, Cazzola M, and Orlandi A (2011a) Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. Br J Pharmacol 163: 1740-1754.
43. Matera MG, Calzetta L, Passeri D, Rogliani P, and Orlandi A (2013) Epithelialsmooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. Pulm Pharmacol Ther 26:156-157.
44. Matera MG, Calzetta L, Segreti A, and Cazzola M (2012) Emerging drugs for chronic obstructive pulmonary disease. Expert Opin Emerg Drugs 17:61-82.
45. Matera MG, Page CP, and Cazzola M (2011b) Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 32:495-506.
46. Méhats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, and Conti M (2003) PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J 17:1831-1841.
47. Meletiadis J, Mouton JW, Meis JF, and Verweij PE (2003) In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 47:106-117.
48. Mercier FJ, Naline E, Bardou M, Georges O, Denjean A, Benhamou D, and Advenier C (2002) Relaxation of proximal and distal isolated human bronchi by halothane, isoflurane and desflurane. Eur Respir J 20:286-292.
49. Milara J, Navarro A, Almudéver P, Lluch J, Morcillo EJ, and Cortijo J (2011) Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/ PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy 41: 535-546.
50. Motulsky H (1995) Intuitive Biostatistics, Oxford University Press, New York, Oxford.
51. Motulsky H and Christopoulos A (2004) Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting, Oxford University Press, Oxford.
52. Myou S, Fujimura M, Kamio Y, Hirose T, Kita T, Tachibana H, Ishiura Y, Watanabe K, Hashimoto T, and Nakao S (2003) Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients. Br J Clin Pharmacol 55:341-346.
53. Myou S, Fujimura M, Kamio Y, Ishiura Y, Tachibana H, Hirose T, Hashimoto T, and Matsuda T (1999) Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 160: 817-820.
54. Naline E, Qian Y, Advenier C, Raeburn D, and Karlsson JA (1996) Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle. Br J Pharmacol 118:1939-1944.
55. Rabe KF (1998) Mechanisms of immune sensitization of human bronchus. Am J Respir Crit Care Med 158:S161-S170.
56. Rabe KF, Tenor H, Dent G, Schudt C, Liebig S, and Magnussen H (1993) Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am J Physiol 264:L458-L464.
57. Rogliani P, Calzetta L, Rendina EA, Massullo D, Dauri M, Rinaldi B, Capuano A, and Matera MG (2013) The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. Pulm Pharmacol Ther 26:325-331.
58. Schmidt DT, Watson N, Dent G, Rühlmann E, Branscheid D, Magnussen H, and Rabe KF (2000) The effect of selective and non-selective phosphodiesterase inhibitors on allergen-and leukotriene C(4)-induced contractions in passively sensitized human airways. Br J Pharmacol 131:1607-1618.
59. Schudt C, Tenor H, and Hatzelmann A (1995) PDE isoenzymes as targets for antiasthma drugs. Eur Respir J 8:1179-1183.
60. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, and Manganiello V (2001) Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66:241-277.
61. Singh SP, Mishra NC, Rir-Sima-Ah J, Campen M, Kurup V, Razani-Boroujerdi S, and Sopori ML (2009) Maternal exposure to secondhand cigarette smoke primes the lung for induction of phosphodiesterase-4D5 isozyme and exacerbated Th2 responses: rolipram attenuates the airway hyperreactivity and muscarinic receptor expression but not lung inflammation and atopy. J Immunol 183:2115-2121.
62. Spina D, Ferlenga P, Biasini I, Moriggi E, Marchini F, Semeraro C, and Page CP (1998) The effect duration of selective phosphodiesterase inhibitors in the guinea pig. Life Sci 62:953-965.
63. Tallarida RJ (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298:865-872.
64. Tallarida RJ (2006) An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319:1-7.
65. Tallarida RJ and Raffa RB (2010) The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations. Pharmacol Ther 127:165-174.
66. Tannu SA, Renzetti LM, Tare N, Ventre JD, Lavelle D, Lin TA, Morschauser A, Paciorek J, Bolin DR, and Michel H, et al. (2010) Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors. Br J Pharmacol 161:1329-1342.
67. Torphy TJ (1998) Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157:351-370.
68. Istituto Nazionale dei Tumori-Independent Ethics Committee(2010) From the biobank to the research biorepository: ethical and legal recommendations, Milan, Italy. http://www.progettorol.it/doc/OECI-BIOBANKS-Oct.2010.pdf
69. Watson N, Bodtke K, Coleman RA, Dent G, Morton BE, Rühlmann E, Magnussen H, and Rabe KF (1997) Role of IgE in hyperresponsiveness induced by passive sensitization of human airways. Am J Respir Crit Care Med 155:839-844.
70. Wright LC, Seybold J, Robichaud A, Adcock IM, and Barnes PJ (1998) Phosphodiesterase expression in human epithelial cells. Am J Physiol 275:L694-L700.
71. Yick CY, Zwinderman AH, Kunst PW, Grünberg K, Mauad T, Dijkhuis A, Bel EH, Baas F, Lutter R, and Sterk PJ (2013) Transcriptome sequencing (RNA-Seq) of human endobronchial biopsies: asthma versus controls. Eur Respir J erj01154-2012, doi: 10.1183/09031936.00115412